A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib

Ann Hematol. 2020 Nov;99(11):2715-2717. doi: 10.1007/s00277-020-04178-0. Epub 2020 Jul 15.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Abnormal Karyotype
  • Adenine / analogs & derivatives
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / administration & dosage
  • Biomarkers, Tumor
  • Bortezomib / administration & dosage
  • Chromosomes, Human, Pair 11 / genetics
  • Chromosomes, Human, Pair 11 / ultrastructure*
  • Chromosomes, Human, Pair 14 / genetics
  • Chromosomes, Human, Pair 14 / ultrastructure*
  • Chromosomes, Human, Pair 8 / genetics
  • Chromosomes, Human, Pair 8 / ultrastructure*
  • Cyclin D1 / genetics*
  • Cytarabine / administration & dosage
  • Drug Resistance, Neoplasm
  • Fatal Outcome
  • Gene Duplication
  • Genes, myc*
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy
  • Lymphoma, Mantle-Cell / genetics*
  • Lymphoma, Mantle-Cell / pathology
  • Male
  • Oncogene Proteins, Fusion / genetics*
  • Piperidines
  • Pyrazoles / administration & dosage
  • Pyrimidines / administration & dosage
  • Recurrence
  • Rituximab / administration & dosage
  • Translocation, Genetic*

Substances

  • Biomarkers, Tumor
  • CCND1 protein, human
  • IGH-CCND1 fusion protein, human
  • Oncogene Proteins, Fusion
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • Cytarabine
  • Cyclin D1
  • ibrutinib
  • Rituximab
  • Bortezomib
  • Bendamustine Hydrochloride
  • Adenine